Latvia delays public funding for breast cancer gene tests
Thursday 19th November 2026 on 15:30 in
Latvia
Latvian patients with breast cancer still have to raise money for gene activity tests that can help determine whether chemotherapy is needed after surgery, LSM reports. The Health Ministry had promised to add the tests to state-funded services this year, but says funding could begin only in the second half of next year.
About 1,200 women in Latvia are diagnosed with breast cancer each year. A test costs €3,000 and can help several hundred patients avoid chemotherapy and its side effects. In a pilot project in Latvia, 150 women avoided chemotherapy after taking the test, and the project also demonstrated an economic benefit for the state.
However, the state does not currently cover the cost, so patients regularly turn to the charity Ziedot.lv for help. The ministry’s plan is to start paying for the tests in the second half of next year, but government documents do not make clear where the funding will come from. Ziedot.lv has criticised the practice of promising healthcare funding and then pushing back deadlines, calling it “feeding people promises.”
Artist Ieva Liepiņa had surgery to remove a tumour after a state-funded breast cancer screening mammogram detected it. She needed donations from friends and acquaintances to pay for a test that indicates how effective chemotherapy is likely to be. The uncertainty was frightening, she said.
Liepiņa received an invitation for screening at the beginning of the year. Although she had been eligible for preventive checks for several years, she had not received an invitation before then.